Influence of Pelacarsen on Patients After Myocardial Infarction With High Lp(a) Values (PEMILA)
Influence of Pelacarsen on Arterial Wall Properties and Risk Factors in Patients After Myocardial Infarction With High Lp(a) Values
Sponsor: University Medical Centre Ljubljana
No open prediction endpoints
Endpoints are classified and published by ProgramSignal analysts.
Request endpoint coverageKey Facts
Primary Endpoints (CT.gov)
Ultrasound functional and morphological properties of the arterial wall and Lp (a) concentration
Time frame: Baseline
Concentration of Lp (a) and SNP in the LPA gene
Time frame: Baseline
The effect of pelacarsen on functional and morphological properties of arterial wall after 6 months
Time frame: Baseline
Eligibility Criteria
Inclusion Criteria: * concentration Lp (a) above 700 mg / L, * optimally treated risk factors for cardiovascular events according to currently valid guidelines, * history of myocardial infarction having occurred in the period 3 months to 10 years prior to the screening visit and / or * history of ischemic stroke having occurred in the period 3 months to 10 years prior to the screening visit and / or * clinically significant symptomatic peripheral artery disease. Exclusion Criteria: * uncontrolled hypertension (systolic blood pressure ≥ 160 mmHg and / or diastolic blood pressure ≥ 100 mmHg), * heart failure New York Heart Association (NYHA) class IV, * history of malignancy of any organ system, * history of hemorrhagic stroke or other major bleeding, * platelet count \<140,000 per mm3, * active liver disease or hepatic dysfunction (elevated transaminases above 3 times the norm, elevated bilirubin above 2 times the norm, elevated creatinine kinase above 3 times the norm), * significan…
Read full criteria on CT.gov →✦ Analyst Commentary
Expert commentary on why this trial matters and what to watch for.
Request coverage →